Loading...

Insulet Corporation

PODDNASDAQ
HealthcareMedical - Devices
$311.77
$-5.39(-1.70%)

Insulet Corporation (PODD) Stock Overview

Explore Insulet Corporation’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
22.07%
22.07%
Profit Growth
$5.72
102.76%
EPS Growth
$5.72
101.69%
Operating Margin
16.81%
40.41%
ROE
34.53%
102.76%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
12
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$230.00
Average$267.78
High$322.00

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO

Ms. Ashley A. McEvoy

Employees

3,900

Headquarters

100 Nagog Park, Acton, MA

Founded

2007

Frequently Asked Questions